Management of Urinary Symptoms on the Day of HDR Brachytherapy
For prostate cancer patients undergoing HDR brachytherapy, pre-existing moderate to severe urinary symptoms represent a relative contraindication to the procedure, and patients with bladder outlet obstruction should be optimized with alpha-blocker therapy before implantation to minimize acute urinary retention risk.
Pre-Treatment Assessment and Optimization
Identify High-Risk Patients
Patients with the following characteristics are at increased risk for acute urinary complications on the day of HDR:
- High International Prostate Symptom Score (IPSS) indicating moderate to severe baseline urinary symptoms 1
- History of bladder outlet obstruction requiring catheterization 1
- Prior transurethral resection of the prostate (TURP), which increases risk of acute retention and incontinence 1
- Very large prostate volumes, which make implantation technically difficult 1
Pre-Procedure Medical Management
Patients with significant baseline urinary symptoms should be started on alpha-blocker therapy (alfuzosin, doxazosin, silodosin, tamsulosin, or terazosin) prior to HDR brachytherapy 2. Alpha-blockers improve voiding symptoms within 2-4 weeks and can reduce the risk of acute urinary retention 2.
For patients with very large prostates, neoadjuvant androgen deprivation therapy may be used to cytoreduce prostate volume sufficiently to allow safer brachytherapy 3.
Day-of-Procedure Management
Immediate Post-Implant Period
On the day of HDR brachytherapy, the most common acute urinary complications include:
- Dysuria (36-67% of patients) 4
- Urinary frequency and urgency (54-92% of patients) 4
- Acute urinary retention requiring catheterization (3-9% of patients) 5, 6
Grade 3 genitourinary toxicity occurs in up to 9% of patients but Grade 4 toxicity is rare 5.
Catheter Management
If acute urinary retention occurs on the day of HDR, an alpha-blocker should be prescribed immediately and the patient should complete at least three days of medical therapy prior to attempting trial without catheter 2. Single-fraction HDR schedules (19-20 Gy) are associated with significantly increased catheter use in the first 12 weeks compared to fractionated schedules (2 × 13 Gy) 5.
Symptom Trajectory
Patients should be counseled that urinary symptoms peak at week 2 post-implant but typically return to baseline or better within 6 months 5, 7. IPSS scores significantly increase following HDR-BT but recover within this timeframe 7.
Dosimetric Considerations to Minimize Toxicity
The urethral radiation dose is directly correlated with severity of acute genitourinary toxicity 8, 7. Specifically:
- Urethral V30-V150 values (percentage of urethral volume receiving 30-150% of prescribed dose) are significantly higher in patients developing Grade 2-3 acute toxicity 8
- Urethral D10 and D20 (dose covering 10-20% of urethral volume) correlate with toxicity severity 8
- Bladder V75 (bladder volume receiving 75% of dose) predicts acute Grade 2 urinary retention 7
The urethral dose must be kept as low as possible during treatment planning to reduce acute complications 8.
Common Pitfalls to Avoid
Do not proceed with HDR brachytherapy in patients with:
- Active urinary tract infection (obtain urinalysis first) 9, 2
- Permanent indwelling Foley catheter 1
- Severe baseline bladder outlet obstruction without prior medical optimization 1
Patients who pass a successful trial without catheter after acute retention remain at increased risk for recurrent urinary retention and require close follow-up 2.